About Orbimed
Orbimed is a venture capital firm founded in 1989. It is primarily based out of New York City, United States. As of Apr 2026, Orbimed is an active investor, having invested in 527 companies, with 20 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Pulnovomed Overall, Orbimed portfolio has seen 1 unicorn, 158 IPOs and 132 acquisitions including key companies like Medtronic, Guardant Health and Invitae. A lot of funds co-invest with Orbimed, with names like RA Capital Management sharing a substantial percentage of its portfolio. Orbimed has team of 103 people including 45 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 10 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Deals in last 12 months
Orbimed's List of Top Investments
Orbimed has a portfolio of 527 companies, one of which is a Unicorn. Their most notable investments are in Exsilio and Disc Medicine.Their portfolio spans across United States, China, Israel and 17 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 12 other sectors, across stages such as Series A, Series B and 10 more. Here is the list of top investments by Orbimed:1. Medtronic
Developer of medical equipment for chronic diseases. The company offers solutions to treat more than 30 chronic diseases, including heart failure, Parkinson's disease, urinary incontinence, Down's syndrome, obesity, neurology, chronic pain, spinal disorders, and diabetes. In general surgery products, the company has developed intraoperative neuromonitoring devices, ablation systems, neurostimulation systems, and others. In 2022, the company recorded annual revenues of $30.77B and a net profit of $4.07B.
Key facts about Medtronic
- Founded Year: 1949
- Location: Minneapolis (United States)
- Annual Revenue: $33.5B as on Apr 30, 2025
- Stage: Public
- Employee Count: 101,924 as on Mar 31, 2026
- Investors: Saints Capital, Greyrock Investments and 23 Others
- Latest Funding Round: Grant (prize money), Oct 01, 2022, $*****
- Highlight: Public
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Key facts about Guardant Health
- Founded Year: 2012
- Location: Redwood City (United States)
- Annual Revenue: $982M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $557M
- Employee Count: 4,335 as on Mar 31, 2026
- Investors: Felicis Ventures, Hone Capital and 24 Others
- Latest Funding Round: Post IPO, Nov 05, 2025, $*****
- Highlight: Public
3. Invitae
Provider of home-based genetic tests for individuals. The platform enables users to request a test online with the help of doctors to collect saliva samples to detect genetic diseases. Users can get results online and share them with doctors.
Key facts about Invitae
- Founded Year: 2010
- Location: San Francisco (United States)
- Annual Revenue: $516M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $190M
- Employee Count: 695 as on Mar 31, 2026
- Investors: Scheuermann Investment, Wellington and 22 Others
- Latest Funding Round: Post IPO, Apr 05, 2021, $*****
- Highlight: Public
4. Insulet
Manufacturer of wearable, tubeless insulin delivery systems for diabetes management. The company develops and provides simple, connected devices for continuous insulin delivery. These devices offer an alternative to multiple daily injections. The company focuses on research and development to improve its technologies.
Key facts about Insulet
- Founded Year: 2000
- Location: Boston (United States)
- Annual Revenue: $2.71B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $120M
- Employee Count: 4,957 as on Mar 31, 2026
- Investors: Piper Jaffray, Deerfield and 13 Others
- Latest Funding Round: Post IPO, Jun 03, 2014, $*****
- Highlight: Public
5. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Annual Revenue: $2.31B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 5,591 as on Mar 31, 2026
- Investors: Harmony Partners, RA Capital Management and 17 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $*****
- Highlight: Public
Orbimed's Year-on-Year Investment Trends
Orbimed has invested in 532 companies over the last 27 years, with an average of 27 new investments annually in the last 10 years. In 2025, it made 38 investments, while as of Apr 2026, it has made 16 investments in this year. Its most recent first time investment was in Sidewinder Therapeutics and most recent follow-on round was in Pulnovomed.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 10 | 6 | 16 |
2025 | 18 | 20 | 38 |
2024 | 26 | 14 | 40 |
2023 | 20 | 18 | 38 |
2022 | 20 | 13 | 33 |
2021 | 57 | 20 | 77 |
2020 | 38 | 23 | 61 |
2019 | 20 | 20 | 40 |
2018 | 21 | 15 | 36 |
2017 | 26 | 19 | 45 |
Orbimed's Investments by Stage
Orbimed has made 133 investments in Series A stage with an average round size of $56.3M, 108 investments in Series B stage with an average round size of $58.5M and 64 investments in Series C stage with an average round size of $73.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 133 |
Series B | 108 |
Series C | 64 |
Post IPO | 43 |
Series D | 33 |
Others | 47 |
Note: We have considered here, only first round of investments
Orbimed's Investments by Sector
Orbimed has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, Enterprise Applications and HealthTech. Notably, it has invested in 416 Tech companies, 405 Enterprise (B2B) companies, 79 Software companies and at least 42 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 349 |
High Tech | 62 |
Healthcare | 55 |
Enterprise Applications | 41 |
HealthTech | 34 |
Others | 68 |
Note: We have considered here, only first round of investments
Orbimed's Investments by Geography
Orbimed has made most investments in United States (268), followed by China where it has made 50 investments.Country | No. of Investments |
|---|---|
United States | 268 |
China | 50 |
Israel | 29 |
India | 24 |
Canada | 13 |
Others | 46 |
Note: We have considered here, only first round of investments
Orbimed's recent investments
Orbimed has made 16 investments in 2026 so far. Pulnovomed and Adcendo are the latest among them.Here are the most recent investments by Orbimed:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 20, 2026 | United States | Series C | 4911 | [+5] | |
Apr 14, 2026 | Denmark | Series C | 7130 | [+15] | |
Apr 10, 2026 | United States | Series C | 5771 | ||
Apr 08, 2026 | United States | Series B | 8413 | ||
Apr 07, 2026 | United States | Series C | 4252 | - |
Unicorns in Orbimed's Portfolio
Orbimed has 1 unicorn in its portfolio - API Holdings. The most recent unicorn in their portfolio is API Holdings which became a unicorn in 2021.Here is a list of unicorns in Orbimed's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
67 | Digital healthcare management tool | 2012 | Mumbai | Series F | jgthf{q |
IPOs and Publicly Listed companies in Orbimed's Portfolio
158 of Orbimed's portfolio companies have become public. Shenzhen Jingfeng Medical Technology got listed on the Hong Kong Exchanges (HKG), in Jan 2026 at marketcap of $2.15B and In Silico got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.72B.Here are Orbimed's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 08, 2026 | Nov 08, 2021 | Series C | 7517 | |
Dec 30, 2025 | Jun 22, 2021 | Series C | 1090 | |
Jun 18, 2025 | Oct 27, 2020 | Series D | 1253 | |
Feb 07, 2025 | Apr 19, 2022 | Series B | 1873 | |
Dec 06, 2024 | Dec 28, 2016 | Series B | 6626 |
Acquired companies in Orbimed's Portfolio
132 companies from Orbimed's portfolio have been acquired. The most recent acquisition were Terns Pharmaceutical in Mar 2026 by Merck.Here are Orbimed's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 25, 2026 | Oct 30, 2018 | Series B | 5436 | |
Feb 23, 2026 | Aug 24, 2009 | Series D | 2813 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 3922 | |
Jan 12, 2026 | - | - | 2172 | |
Jan 07, 2026 | Mar 09, 2021 | Series B | 1348 |
Team profile of Orbimed
Orbimed has a team of 103 members including 45 Partners, 13 Venture Partners and 23 Principals located in United States, China and 3 more locations. Orbimed's team sits on the board of 7 companies.Here is a list of top team members in Orbimed:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | - | |
Partner | Bellevue | - | - | |
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - |
Co-investors of Orbimed
Over the past 27 years, 2277 investors have co-invested in Orbimed's portfolio companies. This includes funds and angels.
- Invested before Orbimed: HHS, Versant Ventures and 954 others have invested in rounds before Orbimed. There are 17 companies where HHS has invested before Orbimed and 11 companies where Versant Ventures has invested before Orbimed.
- Top Co-investors of Orbimed: 633 investors entered a company along with Orbimed. These include investors like RA Capital Management (32 companies).
- Invested after Orbimed: A total of 688 investors have invested in Orbimed's portfolio after their investments. Top Investors include RA Capital Management (22 companies), Perceptive Advisors (15 companies) and Fidelity Investments (13 companies).
Recent News related to Orbimed
•
Nucleus RadioPharma Secures $50M for ManufacturingTcbmag•Apr 22, 2026•Eclipse, Nucleus RadioPharma, Mayo Clinic, Orbimed
•
Pulnovo Medical Announces Strategic Investment from Medtronic in $100 Million FinancingPR Newswire•Apr 20, 2026•Medtronic, Pulnovomed, LAV, HSG and 4 others
•
Adcendo ApS Completes $75 Million Series C FinancingCNW•Apr 14, 2026•Jeito, Bpifrance, Danmarks Eksport og Investeringsfond, Adcendo and 12 others
•
•
•
StairMed Raises RMB 500M in FundingFinSMEs•Apr 02, 2026•LAV, StairMed Technology, FountainBridge Capital, Oriza Holdings and 5 others
•
Pinnacle raises an $89M series B for its oral peptide programsBioWorld•Mar 26, 2026•Pinnacle Medicines, LAV, Foresite Capital, Logos and 4 others
•
Congruence Therapeutics Raises $39.5M in FundingFinSMEs•Mar 23, 2026•Congruence Therapeutics, Dimensions, Amplitude, Invest Quebec and 5 others
•
Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML)HMP Global Learning Network•Mar 19, 2026•Thrombolex, Orbimed
•
OrbiMed Jumps to Number One on the Top 100 List of Biotech Venture InvestorsEndpoints•Feb 26, 2026•Orbimed
